A Study of Amivantamab and Olomorasib Combination Therapy
Phase 1/2
60
about 2.9 years
18+
6 sites in CA, NY, PA +3
About this study
This trial is testing the best dose of amivantamab and olomarasib, a combination treatment, for people with metastatic non-small cell lung cancer. The goal is to see how well this combination slows down or stops tumor growth.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Amivantamab
- 2.Take Olomorasib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
amivantamab
Primary: Phase 1: Number of Participants with Adverse Events (AEs) by Severity, Phase 2: Confirmed Objective Response Rate (ORR)
Secondary: Number of Participants with Adverse Events (AEs) by Severity, Phase 2: Disease Control Rate (DCR), Phase 2: Duration of Response (DoR), Phase 2: Overall Survival (OS), Phase 2: Progression-Free Survival (PFS)
Oncology